Cancer Cell. 2012 Jul 10;22(1):7-8. doi: 10.1016/j.ccr.2012.06.009.

The future of cancer treatment: will it include immunotherapy?

Source

Diabetes Center, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA. jeff.bluestone@ucsf.edu

Abstract

Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells.

Comment on

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. [N Engl J Med. 2012]
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. N Engl J Med. 2012 Jun 28; 366(26):2455-65. Epub 2012 Jun 2.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. [N Engl J Med. 2012]
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. N Engl J Med. 2012 Jun 28; 366(26):2443-54. Epub 2012 Jun 2.

PMID:: 22789534; [PubMed]

Publication Types

Comment

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Supplemental Content

Save items

Related citations in PubMed

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. [Proc Natl Acad Sci U S A. 2002]
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Proc Natl Acad Sci U S A. 2002 Sep 17; 99(19):12293-7. Epub 2002 Sep 6.
Review Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. [Curr Opin Investig Drugs. 2010]
Review Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
Kline J, Gajewski TF. Curr Opin Investig Drugs. 2010 Dec; 11(12):1354-9.
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. [Mol Immunol. 2008]
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Zhang P, Su DM, Liang M, Fu J. Mol Immunol. 2008 Mar; 45(5):1470-6. Epub 2007 Oct 24.
Review Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. [Semin Oncol. 2010]
Review Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J. Semin Oncol. 2010 Oct; 37(5):430-9.
PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. [Tissue Antigens. 2007]
PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.
Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y, Chen Y, Shi Q, Yu G, Zhang X. Tissue Antigens. 2007 Jan; 69(1):19-27.

See reviews... See all...

Cited by 1 PubMed Central article

Involvement of STAT3 in immune evasion during lung tumorigenesis. [Oncoimmunology. 2013]
Involvement of STAT3 in immune evasion during lung tumorigenesis.
Kida H, Ihara S, Kumanogoh A. Oncoimmunology. 2013 Jan 1; 2(1):e22653.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The future of cancer treatment: will it include immunotherapy?
The future of cancer treatment: will it include immunotherapy?
Cancer Cell. 2012 Jul 10 ;22(1):7-8. doi: 10.1016/j.ccr.2012.06.009.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

The future of cancer treatment: will it include immunotherapy?

Source

Abstract

Comment on

Publication Types

Publication Types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information